Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer

Peregrine's partnership prospects, stock soar after bavituximab doubles overall survival in NSCLC

This article was originally published in Scrip

Executive Summary

Peregrine Pharmaceuticals' stock price soared 46.6% on 7 September after the company announced that bavituximab plus the chemotherapy standard docetaxel doubled median overall survival (OS) compared to docetaxel alone, according to the interim analysis of an ongoing Phase IIb clinical trial in refractory non-small cell lung cancer (NSCLC).

Table

View full table

Topics

Tags:
Cancer
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC018700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By